Stereotaxis Inc.
STXS Healthcare Medical Instruments & Supplies
Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow STXS
Stereotaxis Inc. (STXS) Altman Z-score
Stereotaxis Inc.'s Altman Z-score for fiscal 2025 is −12.40, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −12.40 | 2.18 |
| FY2024 | −14.58 | (0.35) |
| FY2023 | −14.23 | (5.09) |
| FY2022 | −9.14 | (11.35) |
| FY2021 | 2.22 | (0.98) |
| FY2020 | 3.20 | 4.34 |
| FY2019 | −1.14 | 30.25 |
| FY2018 | −31.39 | 32.07 |
| FY2017 | −63.46 | (31.82) |
| FY2016 | −31.64 | 1.54 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.22 | — | 0.26 | |
| Retained earnings / total assets | (11.16) | — | −15.63 | |
| EBIT / total assets | (0.42) | — | −1.40 | |
| Market value of equity / total liabilities | 6.24 | — | 3.74 | |
| Sales / total assets | 0.62 | — | 0.62 | |
| Altman Z-score | Distress zone | −12.40 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −37.21 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UTMD Utah Medical Products, Inc. compare | 36.3× |
| KRMD KORU Medical Systems, Inc. compare | 14.5× |
| PDEX Pro-Dex, Inc. compare | 7.4× |
| POCI Precision Optics Corp. compare | 0.6× |
| ZTEKF Zentek Ltd. compare | −2.1× |
| NYXH Nyxoah SA compare | −4.4× |
| STXS Stereotaxis Inc. | −12.4× |
| MBOT Microbot Medical Inc. compare | −19.4× |
| DXR Daxor Corporation compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets